# Clinical Governance Framework for AI-Assisted Clinical Decisions

## Executive Summary

This document establishes the clinical governance framework for the Healthcare AI Assistant, ensuring responsible deployment and oversight of AI-assisted clinical decision support. The framework addresses the unique challenges of integrating artificial intelligence into clinical workflows while maintaining patient safety, regulatory compliance, and clinical accountability. By implementing robust governance structures, we ensure that AI technology enhances rather than replaces clinical judgment, with clear lines of responsibility and comprehensive oversight mechanisms.

The governance framework aligns with NIST AI Risk Management Framework guidelines, HIPAA compliance requirements, and Joint Commission standards for healthcare technology deployment. This document serves as the foundational governance policy for all AI-assisted clinical activities, providing the structural framework within which the governance committee operates.

## 1. Governance Committee Purpose and Scope

### 1.1 Committee Purpose

The Governance Committee exists to provide independent oversight of AI-assisted clinical decisions, ensuring that the Healthcare AI Assistant operates within established clinical, ethical, and regulatory boundaries. The committee's primary responsibility is to protect patient safety while enabling beneficial innovation in clinical decision support. This dual mandate requires balancing technological capability with clinical prudence, ensuring that AI recommendations enhance rather than compromise the quality of patient care.

The committee serves as the ultimate authority for all matters concerning AI system deployment, usage policies, incident review, and ongoing performance monitoring. All significant decisions regarding the AI system require committee review and approval, ensuring that no single individual bears inappropriate responsibility for system-wide decisions. This collective oversight approach distributes accountability appropriately while maintaining decision-making efficiency through clear protocols and delegated authorities.

Furthermore, the committee acts as the primary interface between technical teams, clinical staff, compliance personnel, and executive leadership. This bridging function ensures that technical capabilities are understood in clinical context, that clinical needs inform technical development, and that regulatory requirements are embedded throughout the system's operation. The committee's deliberations and decisions create the linkage between organizational strategy and operational implementation.

### 1.2 Scope of Oversight

The committee's oversight encompasses the complete lifecycle of AI-assisted clinical decisions, from initial system deployment through ongoing monitoring and continuous improvement. This comprehensive scope ensures that all aspects of AI operation receive appropriate scrutiny, with oversight intensity calibrated to risk level and decision significance. The committee reviews both technical performance metrics and clinical outcome indicators, recognizing that AI system effectiveness must be measured in clinical impact rather than technical metrics alone.

Within this lifecycle, the committee specifically oversees clinical accuracy and safety, ensuring that AI recommendations align with current clinical evidence and do not expose patients to unreasonable risk. The committee monitors system performance against established benchmarks, reviewing cases where AI recommendations diverged from clinical consensus and assessing whether such divergences represent system errors or legitimate clinical variation. This retrospective review informs prospective improvements to system behavior and clinical usage guidelines.

The committee also oversees regulatory compliance, ensuring that all AI-assisted clinical activities meet applicable federal and state requirements. This includes HIPAA privacy and security requirements, FDA regulations regarding clinical decision support software, state medical board requirements for telehealth and AI-assisted diagnosis, and accreditation standards from bodies such as The Joint Commission and DNV GL Healthcare. Compliance oversight extends beyond the AI system itself to encompass all organizational activities involving AI-assisted clinical decisions.

### 1.3 Committee Membership Requirements

The Governance Committee comprises five essential roles, each bringing distinct expertise and perspective to committee deliberations. This diverse composition ensures that clinical, technical, ethical, compliance, and patient-centered viewpoints inform all committee decisions. The membership structure reflects the multifaceted nature of AI governance, recognizing that no single expertise domain suffices for responsible oversight of AI-assisted clinical decisions.

**Committee Chair** serves as the presiding officer of all committee meetings and holds ultimate responsibility for committee operations. The Chair must possess clinical informatics expertise demonstrating deep understanding of how clinical information systems affect patient care, combined with a Doctor of Medicine (MD) or Doctor of Osteopathy (DO) degree ensuring full clinical licensure and authority. This individual chairs all meetings, sets agendas in consultation with committee members, breaks tie votes when necessary, and represents the committee to organizational leadership and external stakeholders. The Chair's clinical informatics background ensures that committee discussions remain grounded in practical clinical workflow considerations while their medical degree provides the credentialing necessary for clinical decision-making authority.

**Clinical Lead** provides clinical expertise regarding AI system behavior, recommendation quality, and clinical workflow integration. This role requires AI/ML certification demonstrating formal training in machine learning concepts and applications, combined with active clinical practice experience ensuring current understanding of clinical workflows and patient care standards. The Clinical Lead reviews all clinical recommendations made by the AI system, assesses system performance against clinical benchmarks, and serves as the primary clinical authority regarding system capabilities and limitations. This individual also serves as the main point of contact between the committee and clinical staff using the AI system.

**Compliance Officer** ensures that all AI-assisted clinical activities meet regulatory requirements and organizational policies. This role requires HIPAA certification demonstrating comprehensive understanding of healthcare privacy and security requirements, combined with demonstrated experience in healthcare regulatory compliance. The Compliance Officer reviews all committee decisions for regulatory implications, ensures that incident reporting meets applicable requirements, and maintains documentation demonstrating organizational compliance efforts. This individual also coordinates with external regulatory bodies during audits and investigations.

**Ethicist** provides ethical analysis and guidance regarding AI-assisted clinical decisions, ensuring that technological capabilities align with fundamental ethical principles of healthcare. This role requires bioethics certification demonstrating formal training in ethical analysis applied to healthcare contexts, combined with demonstrated experience in clinical ethics consultation. The Ethicist reviews all committee decisions for ethical implications, particularly regarding issues of autonomy, beneficence, non-maleficence, and justice as they apply to AI-assisted care. This individual also serves as the primary contact for ethics consultations regarding AI system usage.

**Patient Representative** ensures that patient perspectives inform all committee deliberations and decisions. This role requires lived experience as a patient within the healthcare system the AI serves, providing firsthand understanding of patient concerns regarding AI-assisted clinical care. The Patient Representative reviews all committee decisions for patient-centered implications, advocates for patient interests in committee discussions, and serves as the voice of patients who cannot directly participate in governance decisions. This individual also helps communicate committee decisions and policies to patient communities.

## 2. Meeting Schedule and Emergency Procedures

### 2.1 Regular Meeting Schedule

The Governance Committee convenes monthly for regular business meetings, providing consistent oversight while avoiding meeting fatigue that could reduce engagement and effectiveness. Regular meetings occur on the second Tuesday of each month at 10:00 AM local time, with meetings lasting approximately two hours. This scheduling accommodates clinical workflows while providing sufficient time for comprehensive agenda item review. The monthly rhythm ensures that significant issues receive timely attention while allowing adequate time for investigation and analysis between meetings.

Each regular meeting follows a structured agenda that includes review of AI system performance metrics, review of any incidents occurring since the previous meeting, discussion of pending policy matters, and new business introduction. The agenda distributes time appropriately between standing items requiring consistent attention and emerging issues requiring discussion. Meeting materials distribute to all committee members at least five business days before each meeting, ensuring adequate preparation time. This advance distribution allows members to identify relevant issues, consult with experts in their domains, and formulate thoughtful contributions to discussions.

Meeting minutes document all decisions, discussion points, and action items arising from each meeting. Minutes prepare within five business days following each meeting and distribute to all committee members for review and approval at the subsequent meeting. Approved minutes archive permanently in the organizational compliance record system, providing an audit trail of all committee deliberations and decisions. This documentation supports organizational accountability and enables retrospective review of governance decisions.

### 2.2 Emergency Session Protocols

Emergency sessions convene when circumstances require committee action before the next regular meeting. Emergency sessions may be called by the Chair, Clinical Lead, Compliance Officer, or any two committee members acting jointly. The calling party must specify the emergency nature of the situation and provide as much advance notice as circumstances permit. Emergency sessions may convene via video conference or telephone to enable rapid response regardless of member geographic distribution.

Emergency session procedures streamline decision-making while maintaining appropriate oversight. Discussion time reduces to permit rapid resolution, but all members must have opportunity to voice concerns before any decision. Quorum requirements remain unchanged for emergency sessions, ensuring that decisions reflect collective committee judgment rather than availability of individual members. When time constraints preclude convening a full emergency session, the Chair may exercise emergency authority between sessions, subject to ratification at the next regular meeting.

Emergency situations triggering these protocols include critical or high-severity adverse events involving the AI system, regulatory inquiries requiring immediate response, security incidents affecting system integrity, and any situation where delay in committee action could result in patient harm or regulatory violation. The Chair's judgment determines whether circumstances warrant emergency session convening, with deference to committee members' concerns about specific situations.

## 3. Oversight Areas and Responsibilities

### 3.1 Clinical Accuracy Oversight

The committee maintains ongoing oversight of AI system clinical accuracy, ensuring that recommendations align with current clinical evidence and established standards of care. This oversight encompasses multiple dimensions of accuracy including diagnostic accuracy, treatment recommendation appropriateness, medication dosing accuracy, and clinical guideline adherence. The committee reviews aggregated accuracy metrics monthly, investigates any accuracy concerns promptly, and initiates system retraining or usage restriction when accuracy falls below acceptable thresholds.

Clinical accuracy oversight extends beyond aggregate metrics to encompass case-specific review. The committee examines cases where AI recommendations diverged from clinician judgment, assessing whether divergences represent system errors, legitimate clinical variation, or communication issues between AI and human decision-makers. This case-level analysis informs understanding of when AI assistance proves most valuable and where clinician oversight requires greatest vigilance. The committee also reviews cases where clinicians followed AI recommendations that subsequently proved incorrect, assessing whether the error was foreseeable given system limitations.

The committee establishes accuracy benchmarks for different clinical domains, recognizing that AI performance varies across clinical contexts. Critical accuracy thresholds apply to high-stakes decisions such as medication dosing and diagnostic interpretations, while lower thresholds may apply to informational queries and educational content. These differentiated thresholds balance the value of AI assistance against the risks of inappropriate reliance, ensuring that AI capabilities serve clinical needs without creating unacceptable risks.

### 3.2 Patient Safety Monitoring

Patient safety constitutes the committee's highest priority, superseding all other considerations in governance decisions. The committee monitors patient safety continuously through multiple mechanisms including incident reporting systems, clinical outcome tracking, and proactive safety analysis. All safety concerns receive prompt investigation, with findings informing system modifications, usage guideline revisions, and clinician training updates. The committee maintains zero tolerance for preventable patient harm while recognizing that perfect safety in complex clinical environments requires ongoing vigilance and improvement.

Safety monitoring encompasses both actual harm events and near-miss situations where harm was prevented through fortunate circumstances or timely intervention. Near-miss analysis provides valuable learning opportunities by identifying failure modes before they result in actual patient harm. The committee reviews all near-miss events, assessing whether system modifications or process changes could prevent similar situations in the future. This proactive approach to safety management enables continuous improvement before patients experience actual harm.

The committee also monitors safety implications of system changes before deployment. All significant system modifications require safety review by the Clinical Lead, with any safety concerns escalating to full committee review before deployment. This prospective safety assessment ensures that system improvements do not inadvertently introduce new risks while addressing identified limitations. The committee maintains authority to delay or block deployments when safety concerns cannot be adequately mitigated.

### 3.3 Regulatory Compliance Oversight

The Compliance Officer leads committee oversight of regulatory compliance, ensuring that all AI-assisted clinical activities meet applicable requirements. Compliance oversight encompasses HIPAA privacy and security requirements, FDA regulations regarding clinical decision support software, state medical board requirements, and accreditation standards. The committee receives quarterly compliance reports summarizing organizational compliance status and any compliance concerns requiring attention. Significant compliance gaps trigger immediate remediation efforts with progress reporting to the committee until resolution.

Regulatory compliance oversight extends to proactive preparation for regulatory changes. The committee monitors developments in healthcare AI regulation, assessing how emerging requirements might affect organizational AI usage. This forward-looking compliance approach enables proactive adaptation to regulatory changes rather than reactive compliance after new requirements take effect. The committee also coordinates with legal counsel regarding regulatory interpretation and compliance strategy.

Documentation practices ensure that organizational compliance efforts remain defensible in regulatory inquiries or audits. The committee maintains comprehensive records of compliance activities, including policy decisions, training completion, incident handling, and system modifications. This documentation demonstrates organizational commitment to compliance and provides evidence of reasonable efforts to meet regulatory requirements. The committee reviews documentation practices annually to ensure completeness and accuracy.

### 3.4 Ethical Use Oversight

The Ethicist leads committee oversight of AI system ethical implications, ensuring that technological capabilities align with fundamental healthcare ethical principles. Ethical oversight addresses issues including appropriate informed consent for AI-assisted care, fair access to AI benefits across patient populations, transparency regarding AI involvement in clinical decisions, and preservation of human agency in clinical decision-making. The committee reviews policies and practices against ethical principles, identifying and addressing concerns through policy modification or additional safeguards.

Ethical oversight extends to assessment of AI system biases that might affect clinical recommendations differentially across patient populations. The committee reviews system performance metrics disaggregated by demographic characteristics, assessing whether the AI system provides equitable assistance across all patient groups. Any identified biases trigger investigation and remediation efforts, with ongoing monitoring to verify that remediation achieves intended effects. This commitment to equitable AI assistance reflects organizational values and regulatory requirements regarding non-discriminatory healthcare delivery.

The committee also addresses ethical questions regarding the appropriate scope of AI involvement in clinical decisions. As AI capabilities expand, the boundary between AI assistance and AI substitution blurs. The committee establishes and maintains clear policies regarding which decisions require human judgment and which may incorporate AI input, ensuring that AI augments rather than replaces clinical reasoning. These policies evolve as AI capabilities and clinical experience with AI assistance develop.

## 4. Escalation Policies and Decision Authority

### 4.1 Severity-Based Escalation Framework

The committee establishes clear escalation paths for different severity levels, ensuring that concerning situations receive appropriate attention regardless of when they occur. Escalation protocols specify who receives notification, what actions are required, and timelines for response at each severity level. This structured approach ensures that serious situations receive immediate attention while avoiding alarm fatigue from over-escalation of routine matters. Escalation triggers and protocols communicate to all relevant personnel, enabling appropriate response when concerning situations arise.

**Critical Severity** applies to situations where AI system behavior has caused or nearly caused patient harm. Critical escalations require immediate notification of the Chair, Clinical Lead, and Compliance Officer, with emergency session convening within 24 hours. Critical situations also require notification of executive leadership including the Chief Medical Officer and Chief Executive Officer. Immediate actions may include system shutdown pending investigation, clinician notification of affected patients, and regulatory notification as required. All critical escalations require formal investigation with findings reported to the committee.

**High Severity** applies to situations where AI system behavior created significant risk even if no harm occurred. High escalations require notification of the Clinical Lead and Compliance Officer within 4 hours, with investigation beginning within 24 hours. High severity situations may require interim usage restrictions pending investigation findings. The committee reviews all high severity escalations at the next regular meeting, with investigation status and preliminary findings reported.

**Medium Severity** applies to situations where AI system behavior deviated from expected performance without significant risk. Medium escalations require documentation within 24 hours and review by the Clinical Lead within 72 hours. The committee receives weekly reports on medium severity escalations, with patterns or trends identified for committee attention. Investigation of medium severity situations occurs as time permits but prioritizes higher severity matters.

**Low Severity** applies to situations where AI system behavior deviated from optimal but caused no risk. Low escalations require documentation within 48 hours for aggregate reporting. The committee reviews low severity escalations monthly in aggregate, identifying patterns that might indicate developing system issues. Low severity matters typically do not require individual investigation unless patterns emerge.

### 4.2 Decision-Making Authority

The committee holds decision-making authority for all matters within its oversight scope. Committee decisions require quorum consisting of at least four of five members present, with decisions adopted by majority vote of those present. The Chair breaks tie votes when committee members divide equally. These quorum and voting requirements ensure that decisions reflect collective judgment while enabling decisions when full attendance is not possible.

Certain decisions require supermajority approval reflecting their significance. Constitutional changes affecting committee structure or authority, system deployment decisions, and policy changes with organization-wide implications require two-thirds majority approval. These elevated approval thresholds ensure that consequential decisions receive broad support and thorough consideration. The requirement for supermajority approval does not apply to routine operational decisions within established policies.

Between committee meetings, the Chair holds authority to act on matters requiring immediate attention. Chair authority extends to emergency decisions that cannot wait for full committee convening, interim measures pending full committee review, and administrative matters not affecting policy or system operation. Chair actions require report to the full committee at the next meeting, with ratification as appropriate. Chair authority does not extend to matters explicitly requiring full committee deliberation, such as policy changes or deployment approvals.

## 5. Performance Monitoring and Continuous Improvement

### 5.1 Key Performance Indicators

The committee monitors AI system performance through defined key performance indicators spanning clinical, technical, operational, and user experience dimensions. Clinical indicators include recommendation accuracy rates, citation verification rates, and clinician override frequencies. Technical indicators include system availability, response latency, and error rates. Operational indicators include usage volumes, user satisfaction scores, and training completion rates. These indicators provide quantitative foundation for oversight decisions, supplementing qualitative assessment with objective metrics.

Indicator targets establish minimum acceptable performance levels, with performance below targets triggering investigation and remediation efforts. Targets derive from organizational requirements, regulatory expectations, and industry benchmarks where applicable. The committee reviews targets annually, adjusting as appropriate based on experience and evolving standards. Target setting balances aspiration with realism, establishing challenging but achievable goals that drive continuous improvement without creating perverse incentives.

Trend analysis supplements point-in-time indicator assessment, revealing trajectory and identifying developing issues before they manifest as significant problems. The committee receives monthly indicator reports with trend analysis, enabling assessment of whether system performance improves, degrades, or remains stable over time. Declining trends trigger investigation even when current performance remains above targets, enabling proactive intervention before performance degradation reaches concerning levels.

### 5.2 Continuous Improvement Process

The committee drives continuous improvement through structured review and enhancement cycles. Following each incident investigation or performance review, the committee identifies improvement opportunities and assigns action items for implementation. Improvement actions may include system modifications, policy changes, training updates, or process refinements. The committee tracks all improvement actions to completion, verifying that intended improvements actually achieve expected effects.

Annual strategic review assesses overall governance effectiveness and identifies opportunities for enhancement. This review examines committee processes, oversight mechanisms, and governance outcomes, identifying areas where governance practices could improve. Strategic review findings inform governance policy modifications, resource allocation decisions, and committee development priorities. This systematic approach to governance improvement ensures that committee practices evolve alongside the AI system and organizational experience.

The committee also learns from external sources including peer organizations, academic research, regulatory guidance, and industry best practices. Committee members maintain awareness of AI governance developments through professional development activities and information sharing with peer organizations. Relevant findings from external sources inform committee deliberations and policy recommendations, ensuring that organizational governance benefits from collective experience rather than learning only from direct experience.

## 6. Policy Review and Governance Evolution

### 6.1 Annual Policy Review

The committee conducts comprehensive review of all governance policies annually, ensuring continued alignment with organizational needs, regulatory requirements, and best practices. Annual review examines each policy for continued relevance, effectiveness, and appropriateness given accumulated experience and evolving circumstances. Policy review may result in policy continuation, modification, or retirement, with modifications reflecting lessons learned and emerging requirements.

Annual review also assesses policy coverage, identifying gaps where additional governance policies might improve oversight or address previously unaddressed situations. Policy development follows structured process including problem definition, stakeholder consultation, draft development, comment period, revision, and approval. This deliberate process ensures that new policies address actual needs, consider stakeholder perspectives, and achieve intended effects without creating unintended consequences.

Regulatory changes may trigger extraordinary policy review outside the annual cycle. When regulatory agencies issue new requirements or guidance affecting AI governance, the committee convenes to assess implications and determine whether policy modifications are required. Expedited review processes enable rapid response to regulatory changes while maintaining appropriate deliberation and stakeholder input. The committee tracks regulatory developments continuously, enabling proactive preparation for anticipated regulatory changes.

### 6.2 Governance Framework Amendments

Amendments to this governance framework require supermajority committee approval following deliberation and comment period. Framework amendments affect the fundamental structure and authority of governance, warranting heightened approval requirements and thorough consideration. Amendment proposals may originate from any committee member, from organizational leadership, or from external requirements such as regulatory mandates. All amendment proposals receive public comment period allowing stakeholder input before committee deliberation.

Emergency amendments may bypass standard amendment procedures when circumstances require immediate policy change. Emergency amendments require unanimous committee approval and Chair certification of emergency circumstances. Emergency amendments remain effective for 90 days, after which standard amendment procedures must complete for the amendment to remain in effect. This provision enables rapid response to urgent situations while ensuring that emergency measures receive eventual thorough review.

The governance framework defines the committee's authority and structure, establishing the foundation for all committee operations. Amendment of foundational provisions requires particularly thorough deliberation, recognizing that such amendments affect the committee's fundamental character and capabilities. Provisions regarding membership requirements, committee authority, and decision-making procedures constitute foundational provisions subject to enhanced amendment requirements.
